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• 
C
hronic m
yelogenous leukem
ia 
(C
M
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disproportionate am
ount of w
hite 
blood cells in bone m
arrow
. 
• 
Im
atinib, a relatively new
 drug 
(approved in the U
S
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M
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• 
75%
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patients eventually relapse after 
continuous treatm
ent. 
• 
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the efficacy of strategic treatm
ent 
interruptions via num
erical 
sim
ulations. 
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The delay differential equation 
m
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atical m
odel w
as pioneered 
by M
ichor et al. and later adjusted to 
include an im
m
une T cell response 
via m
ass action term
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• 
N
eural netw
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inspired m
achine learning 
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s used to approxim
ate 
functions. 
 • 
W
e are at liberty to train the neural 
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ork w
ith any am
ount of noise 
and any tim
e intervals such as 
w
eekly or m
onthly data. 
• 
The neural netw
ork predicts the 
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different T-cell curves. 
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e for each 
sim
ulation. 
• 
W
e add G
aussian noise to account 
for instrum
entation and m
odel 
error. 
• 
W
e use this data to train a neural 
netw
ork and asses its accuracy. 
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realistic T-cell distributions.  
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Abstract
Chronic myelogenous leukemia (CML) is a cancer of the white blood cells that results from uncontrolled growth
of myeloid cells in the bone marrow and the accumulation of these cells in the blood. The most common form of
treatment for CML is imatinib, a tyrosine kinase inhibitor. Although imatinib is an eﬀective treatment for CML
and most patients treated with imatinib do attain some form of remission, imatinib does not completely eradicate
all leukemia cells, and if treatment is stopped, all patients eventually relapse In [1], the authors constructed a
system of delay diﬀerential equations to mathematically model the dynamics of anti-leukemia T-cell responses to
CML during imatinib treatment. Using the insights provided by the model, Kim et al. [1] and Paquin et al.
[2], [3] proposed alternative treatment strategies for CML. While those works demonstrated the usefulness of the
mathematical model for studying novel treatment regimes to enhance imatinib therapy, the initial works did not
study the mathematics of the roles played by the particular numerical values of the model parameters in detail.
In this work, we conduct a comprehensive study of the model parameters using numerical methods and statistical
models. Specifically, we adjust the parameter values one at a time for each of three representative CML patients
to identify the mathematical and numerical significance of the individual parameter values. We discover that the
average number of T-cell divisions per day is the single most important parameter for predicting the dynamics
between T-cells and leukemia cells, and we study the mathematics of the role played by this parameter in the
context of alternative treatment strategies for CML.
In particular, we study the eﬀect of the average number of T-cell divisions per day on the eﬃcacy of strategic
treatment interruptions (STIs) as a potential therapeutic strategy for CML patients. In STI therapy protocols,
imatinib treatment is temporarily stopped in order to leverage the anti-leukemia immune response. In [3], the
authors demonstrated numerically that STIs may have the potential to completely eradicate leukemia. However,
those studies were experimental in nature, and did not formally address the question of precisely when and/or for
how long to temporarily stop imatinib. In this work, we formally study the impact of the numerical parameters on
the timing and duration of strategic treatment interruptions, and we derive an analytic condition in terms of the
parameter values for the first time at which to temporarily stop imatinib treatment.
References
[1] P. Kim, P. Lee, and D. Levy, (2008), Dynamics and potential impact of the immune response to chronic myelogenous leukemia,
PLoS Computational Biology 4(6).
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Background 
This quarter John, Caleb, and David revisited the leukemia project of summer 2013.  
That summer was mainly concerned with the efficacy of strategic treatment 
interruptions (STI) in the presence of an initial load of resistant leukemia cells.  
Simulations demonstrated that a well-timed STI can lead to elimination of leukemia 
cells for patients 1 and 4 and two well-timed simulations can eliminate leukemia for 
patient 12.   
Introduction 
This quarter we wanted to step away from STIs and focus our efforts on 
understanding the model itself.  To achieve full understanding of the model, we 
varied one parameter at a time, as opposed to varying parameters simultaneously 
in the summer 2013 research.  The goal of this research is to understand exactly 
how each parameter affects the T-cell and leukemia interactions and inform CML 
immunologists of key parameters.    
Methods 
From previous work we have observed that the average number of T-cell divisions 
(n) is a highly volatile parameter: slight variations can dramatically affect the T-cell 
and leukemia concentrations.  For this reason, n is only varied by ± 10%.  Tau is 
varied from 12 hours to 24 hours to aid interpretations.  Every other parameter is 
varied by ± 25%.  Animations of T-cell and leukemia dynamics are created for each 
parameter for each patient and can be found on here (dropbox project page).   
Results 
Overall parameters ay, by, cy, az, bz, and cz had little influence on T-cells and 
leukemia levels.  T-cell concentration would slightly increase and leukemia 
concentration would slightly lower for patients 1 and 4, but not for patient 12.   
Of the death rates for leukemia cells, the death rate for differentiated cells (d2) 
clearly has the highest impact of all the death rates.  From lowest concentration to 
highest concentration, cell concentrations are ranked by stem cells, progenitor cells, 
differentiated cells, and finally terminally differentiated cells.  Increasing the death 
rate for differentiated cells stunts the growth for terminally differentiated cells, 
which account for the bulk of the leukemia concentration.    
Surprisingly, increasing the death rates of leukemia cells has the opposite effect of 
what we would expect.  Increasing the death rate stunts T-cell growth and 
increases leukemia growth.  This is because when the death rate is too low, T-cells 
aren’t stimulated.  The unstimulated T-cells allow the leukemia cells to thrive. 
Across all patients, as the leukemia suppression parameter (cn) is increased, T-cell 
concentration falters and leukemia concentration rises substantially.  In this sense, 
cn behaves similarly to d2.   
The death rate of T-cells (dt) has a minimal effect on patients 1 and 4, but patient 
12’s length of cytogenetic remission time window is significantly shortened as dt is 
increased.   
k, n, p0, and qt behave qualitatively the same.  Each parameter raises T-cell 
concentration and lowers leukemia levels.  n and qt have a much higher impact 
than k and p0. 
qc is unique because it’s the only parameter that lowers both T-cell and leukemia 
concentrations.  However, it only affects the concentrations by a modest amount.   
As lambda is increased, T-cell concentration decreases and minimum cancer rises.  
The cytogenetic remission time window is also shortened.  The T-cell peak also 
moves to an earlier month as lambda approaches 1.  One would think a higher 
lambda would mean lower minimum cancer levels, but this can be explained for the 
same reasons that increasing d2 actually produces adverse effects. 
There is hardly any visible effect as ry is varied.  As rz increases, T-cell and 
leukemia concentrations both increase. 
Varying the T-cell growth rate (st) results in little effect for patients 1 and 4, but 
modestly increases T-cells and decreases leukemia in patient 12. 
Increasing the initial T-cell load (T_0) only modestly increases overall T-cells and 
lowers leukemia.  Overall, this parameter is not significant when varied by ± 25%.  
But we must keep in mind that initial T-cell concentration fluctuates wildly from 
patient-to-patient: T_0 = 3/2500 for patient 1, 1/2500 for patient 4, and 11/2500 
for patient 12. 
Increasing the average time for a T-cell to divide (tau) only modestly lowers T-cell 
concentration and raises leukemia concentrations.  Conclude it’s not a significant 
parameter when fixing all other parameters. 
The mutation rate (u) produces no visible effect when varied ±25%.   
T-cell and leukemia interactions had minimal changes when y0_0 and z0_0 were 
varied.  It may be worth noting that increasing z0_0 simply shortens the 
cytogenetic remission time interval for patient 12. 
In many cases, patients 1 and 4 behaved differently than patient 12.  A natural 
question is to ask, “What makes patient 12 different?”  In this section we analyze 
patient-dependent parameters y0_0, n, dt, cn, and T_0.  Parameter st is not 
included since st’s effect can be ascertained by examining dt and T_0 (assuming 
steady state).  Below are plots comparing patient-dependent parameters.   
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At first glance, it seems that cn should actually distinguish patients 1 and 12 from 
patient 4.  But patient 4’s high cn is balanced by his/her high value of n.  After 
several simulations, it’s clear that patient 12’s high value of dt is actually the 
principal cause for patient 12’s irregular behavior.  Varying the parameters didn’t 
catch this since dt was only varied from .0053 to .0088 for patient 12: nowhere 
near patient 1’s value of .0019.  It’s important to compare to patient 1’s value since 
patient 1 and patient 12 have a similar n value.   
Conclusion  
This work gives an in-depth analysis for each parameter and attempts to explain 
the key differences between patients 1 and 4 from patient 12.  Some non-obvious 
highlights include: 
• d2 is a significant parameter when all other parameters are fixed.  Higher d2 
means fewer T-cells and more leukemia, which is counter-intuitive. 
• n and qt are driving much of the model’s dynamics. 
• Higher lambda actually means fewer T-cells and more leukemia, which again 
is counter-intuitive. 
• qc is the only parameter that decreases both T-cells and leukemia. 
• Patient 12’s high T-cell death rate accounts for patient 12 having different 
reactions to varying parameters.  The high T-cell death rate also accounts for 
unsuccessful single STIs and needing two STIs to achieve elimination. 
• Based on this research, dt can be an important parameter in determining if a 
patient needs 1 STI or 2 STIs. 
 
We hope to further characterize patient dynamics.  Many questions still remain: 
When is the optimal time to implement an STI?  Does an optimal time even exist?  
Is it possible to determine the time analytically given a set of patient parameters?  
Is it possible to determine the time before parameters are even known?  We believe 
this in-depth analysis of patient parameters is good first step to answering some of 
these questions. 
 
 
 
 
 
A Neural Network Approach to Predict Optimal Treatment
Strategy for Chronic Myelogenous Leukemia
John Shamshoian, Dana Paquin
June 6, 2015
Abstract
Your abstract.
1 Introduction
dy0
dt
= [ry(1  u)  d0]y0, (1)
dy1
dt
= ayy0   d1y1,
dy2
dt
= byy1   d2y2,
dy3
dt
= cyy2   d3y3,
dz0
dt
= (rz   d0)z0 + ryuy0,
dz1
dt
= azz0   d1z1,
dz2
dt
= bzz1   d2z2,
dz3
dt
= czz2   d3z3,
Remission level Hematologic Cytogenetic Molecular
Concentration (k/µL) 1.67 1.67 · 10 2 1.67 · 10 4
Table 1: Leukemia cell concentrations (in k/µL) corresponding to hematologic, cytogenetic, and
molecular remission levels.
1
1.1 Delay Di↵erential Equation Model
dy0
dt
= (ry(1  u)  d0)y0   qCp(C, T )y0, (2)
dy1
dt
= ayy0   d1y1   qCp(C, T )y1,
dy2
dt
= byy1   d2y2   qCp(C, T )y2,
dy3
dt
= cyy2   d3y3   qCp(C, T )y3,
dz0
dt
= (rz   d0)z0 + ryuy0   qCp(C, T )z0,
dz1
dt
= azz0   d1z1   qCp(C, T )z1,
dz2
dt
= bzz1   d2z2   qCp(C, T )z2,
dz3
dt
= czz2   d3z3   qCp(C, T )z3,
dT
dt
= sT   dTT   p(C, T )C + 2np(Cn⌧ , Tn⌧ )qTCn⌧ ,
where
p(C, T ) = p0e
 cnCkT, C =
3X
i=0
yi +
3X
i=0
zi,
Cn⌧ = C(t  n⌧), Tn⌧ = T (t  n⌧).
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(b) Patient 1 with an STI at month 8
Figure 1: Patient 1 relapses when treated with constant imatinib. However, a well timed STI
will lead to elimination at month 23.
2
Parameter Description Estimate
  Fractional adjustment constant 0.75
d0 Stem cell death rate 0.003  /day
d1 Progenitor cell death rate 0.008  
d2 Di↵erentiated cell death rate 0.05  
d3 Terminal cell death rate  
ry Stem cell regeneration rate 0.008 /day
ay Stem cell growth rate 1.6 (without imatinib treatment)
1.6/100 (with imatinib treatment)
by Progenitor cell growth rate 10 (without imatinib treatment)
10/750 (with imatinib treatment)
cy Di↵erentiated cell growth rate 100
rz Imatinib resistant mutation
stem cell regeneration rate 0.023 /day
az Imatinib resistant
mutation stem cell growth rate 1.6
bz Imatinib resistant mutation
progenitor cell growth rate 10
cz Imatinib resistant mutation
di↵erentiated cell growth rate 100
k Kinetic (mixing) coe cient 1 (k/µL) 1/day
p0 Probability that T-cell engages cancer cell 0.8
qC Probability that cancer cell dies from
encounter with T -cell 0.75
qT Probability that T-cell survives
encounter with cancer cell 0.5
⌧ Duration of one T-cell division 1 day
n Average number of T-cell divisions patient-dependent
dT Anti-leukemia T-cell death rate patient-dependent
sT Anti-leukemia T-cell supply rate patient-dependent
cn Decay rate of immune responsivity patient-dependent
Table 2: Estimates of parameters [1], [2].
3
2 Neural Networks
In this paper we aim to predict the optimal time to interrupt imatinib treatment given a set of
T-cell data. We suspect the optimal timing will be a highly nonlinear function of a patient’s
T-cell concentration over several months. Even though ordinary least squares can fit nonlinear
hypotheses, this method would be unwieldy for the amount of variables and generality in this
problem.
Neural networks, although deemed ”black boxy,” provide for a powerful paradigm of input-
output curve fitting. Neural networks are composed of an input layer, k hidden layers, and
an output layer. Each layer is composed of a set of neurons which act as parameters used in
predicting the response. In the input layer, there is a neuron associated with each input variable
and a ”bias” neuron which resembles the intercept team in linear regression. The hidden layers
each have a ”bias” neuron and any amount of other neurons. The response layer also has a
neuron for each response. For the sake of simplification, we give an overview of neural networks
tailored to our problem. We use Matlab’s neural network toolbox which only uses a single hidden
layer, so k = 1. We’re predicting a single response, so our output layer is just a single neuron.
For this example, we’ll use monthly T-cell data (up to month 6) to predict the optimal treatment
interruption time. Figure 2 displays a visualization of this network. In this example we have six
inputs, eleven hidden neurons (including the bias term), and one response.
Each neuron in one layer sends information to each neuron in the next layer. Let ✓kij denote
jth neuron in the kth layer receiving input from the ith neuron from the previous layer. Denote akj
the jth “activation” in the kth layer. By convention, each a1j is represented by xj to indicate the
activation in the input layer is the input data. In our example, each activation can be calculated
by
a21 = ✓
1
10 + ✓
1
11x1 + ✓
1
12x2
a22 = ✓
1
20 + ✓
1
21x1 + ✓
1
22x2
a23 = ✓
1
30 + ✓
1
31x1 + ✓32x2
Once we compute the activations, we can compute the predicted yˆ as yˆ = a31 = ✓
2
10+ ✓
2
11a
2
1+
✓212a
3
2 + ✓
2
13a
2
3
As usual, we let
Pn
i=1(y   yˆ)2 be the cost function. We use Matlab’s Levenberg-Marquardt
backpropagation optimization algorithm to estimate each ✓kij so that the cost function will be
a local minimum. Once we have each of the ✓kij , we estimate each patient’s optimal treatment
interruption time.
3 Methodology
In order to train any machine learning algorithm, the user must supply training data. Since we
only have 3 patients available, we must simulate thousands of patients and find each of their
optimal treatment interruption times. The optimal interruption time is defined as
• The interruption time such that elimination is achieved the quickest if the patient achieves
elimination at some point
• The interruption time that will yield the minimum cancer concentration if elimination is
never achieved
4
Figure 2: A visual representation of the neural network using monthly T-cell data to predict the
optimal treatment interruption timeA Neural Network Approach to Predict Optimal Treatment
Strategy for Chronic Myelogenous Leukemia.
To simulate random patients, we keep patient independent parameters constant and vary patient
dependent parameters. We average patient estimates of dT , y0, T0, z0 and then sample from a
uniform ±25% of each average. For example, we sample dT from a Unif[dT   25%, dT + 25%]
distribution. If we randomly sample n and cn from a similar uniform distribution, we would attain
many unrealistic T-cell distributions for a CML patient and e↵ectively waste computational
resources.
To avoid training the neural network with too many unrealistic T-cell distributions, we note
two key facts about fitted patient parameters:
1. Parameters n and cn are the two most sensitive parameters, and they are necessarily
positively associated with one another in some way.
2. Parameters n and cn likely do not come from a uniform distribution.
To address the first point, we create a Lagrange interpolating polynomial shown in Figure
3 between n and cn by using patient fitted data. We then add random Gaussian noise to each
simulated cn to account for patient to patient variability.
To address the second point, we find that realistic T-cell distributions arise most frequently
when when we create a Pearson distribution for n. This Pearson distribution is based o↵ patient
fitted values of n and simulation testing. Once we have simulated values of n, we follow the above
process to simulate values of cn. The distributions of n and cn are shown in Figures 4(a) and
4(b), respectively. Once we have simulated patient parameters we numerically find the optimal
interruption time within a two day period. Several simulated T-cell distributions are shown in
Figure 5.
After we acquire simulated T-cell curves, we extract weekly or monthly data to train the
neural network. We use data up until day 180 since the optimal interruption time in our simu-
lations is always greater than this period. In practice, no measurement of T-cell concentration
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Figure 3: Lagrange interpolation between n and cn. The red data points indicate previously
fitted patient n and cn parameters. We interpolate and add random noise as reasonable function
relating n to cn.
is perfect. In order to render our predictions robust against this instrumentation error, we add
Gaussian noise to the T-cell time series data. For example, weekly T-cell time series data with
Gaussian noise following N(µ = 0,  = .001) and N(µ = 0,  = .005) distributions are shown in
Figure 3. In the next section we assess the accuracy of the neural network with varying degrees
of noise while using weekly or monthly data.
4 Results
We train the neural network with 1,500 simulations. Initially we train the neural network with
weekly time intervals and no random noise with results shown in Figure 7. The target is the
delay di↵erential equation model’s prediction for the optimal time and the output is the neural
network’s prediction for the optimal time. The neural network is designed to minimize the mean
squared error between the output prediction and the target prediction.
We randomly divide the simulations into training, validation, and test data in a 70:15:15
ratio. The training set is used to estimate possible parameters of the neural network. The neural
network parameters are first estimated to minimize the cost function of the training data set.
The validation data set tunes the parameters so that the model does not overfit the training
data set. The test data set tests this model with data the model has not seen before. To assess
the accuracy of the neural network, we look at how close the output predictions are to the
target predictions. Figure 7 has a very strong correlation (r = .997) between target and output
timing for the test data set. Therefore this algorithm is quite adept at predicting the optimal
timing prediction from the delay di↵erential equation model. We list other results for weekly
and monthly data with two levels of noise in Table 3 and their associated plots in the Appendix
section.
From Table 3 we see that the model can accurately predict the target optimal time with no
noise present. The level of accuracy is surprising (especially for monthly data) since the neural
network just uses six T-cell data points (one at each month) to predict the optimal time of a
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Figure 4: The Pearson distribution of n on the left is found by fitting a distribution to patient
fitted data and prior knowledge. The distribution of cn on the right is found by interpolation
from Figure 3 and adding Gaussian noise.
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Figure 5: Several T-cell distributions simulated by choosing patient-dependent parameters de-
scribed in the process above.
model involving six patient dependent parameters that are quite di cult to estimate.
The neural network is also robust against modest Gaussian noise levels. When   = .001
the neural network still gives accurate predictions when using either weekly or monthly data.
Unsurprisingly, using weekly data gives slightly more accurate predictions than monthly data.
However, monthly data predictions are still reasonably accurate.
Once we assume high levels of noise, the discrepancy of accuracy between weekly and monthly
T-cell data grows higher. The weekly T-cell data still gives fairly accurate predictions with a
coe cient of correlation of r = .8262. However, using monthly T-cell data gives weak predictions
as r is only .59897. This result suggests to gather weekly T-cell data if we believe a high level of
noise is present when T-cell concentration is measured.
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Figure 6: Visual comparison of T-cell time series data with di↵erent levels of noise. The actual
T-cell data is identical.
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Figure 7: Neural network performance when trained with weekly T-cell data and no random
noise
In the next section we discuss the limitations to this approach.
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Noise level   Time interval period Coe cient of correlation r
0 Weekly .99743
0 Monthly .99684
.001 Weekly .98004
.001 Monthly .9422
.005 Weekly .8262
.005 Monthly .59897
Table 3: Correlations between target timing and output timing for several levels of noise and
timing periods.
5 Discussion
The main limitation of this approach is that we assume the dynamics between T-cells and
leukemia cells can be modeled by the delay di↵erential equation. We only have three patient’s
data available, and even that patient data is taken at sparse monthly intervals. Furthermore,
no leukemia concentration was not measured in those three patients. Since we have such little
data, there’s a lot of room for model error. For example, what if STI’s do not even lower
leukemia concentrations in practice? The model would have to be adjusted. Another limitation
is validating our findings. In practice, patients cannot undergo an arbitrary amount of STI’s
(unlike in simulation). There’s not enough data to know how accurate the delay di↵erential
equation or neural network predictions are to the true optimal time.
Despite these limitations, the neural network approach provides a simple method to find the
optimal time to interrupt if we assume T-cell and leukemia dynamics can be reasonably modeled
by the delay di↵erential equation. Prior to this method, the only alternative would have been
to collect T-cell data and estimate patient dependent parameters before the STI. However, this
would be tricky since parameter estimation is not easy even when we have years of data.
6 Conclusion
This paper provides a framework to determine the optimal time to start a 15 day STI for patients
with chronic myelogenous leukemia. Our results demonstrate that we can accurately predict the
optimal time to start the STI (according to the di↵erential equation model) when no noise or little
noise is present. We confirm the intuition that more measurements translate to more accurate
predictions. Even though this work used the delay di↵erential equation model, the same analysis
can be mimicked under any model by following the same steps outlined in this paper.
Unfortunately, sometimes a single STI isn’t enough to cure leukemia. For example, [3] found
that patient 12 requires two well-timed STIs to achieve elimination. In the future...
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Figure 8: Neural network performance when trained with monthly T-cell data and no random
noise. A test coe cient of correlation of r = .99684 indicates the neural network gives very
accurate predictions.
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Figure 9: Neural network performance when trained with weekly T-cell data and Gaussian noise
of   = .001. A test coe cient of correlation of r = .98004 indicates the neural network gives
very accurate predictions.
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Figure 10: Neural network performance when trained with monthly T-cell data and Gaussian
noise of   = .001. A test coe cient of correlation of r = .9422 indicates the neural network gives
very accurate predictions.
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Figure 11: Neural network performance when trained with monthly T-cell data and Gaussian
noise of   = .005. A test coe cient of correlation of r = .8262 indicates the neural network gives
fairly accurate predictions.
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Figure 12: Neural network performance when trained with monthly T-cell data and Gaussian
noise of   = .005. A test coe cient of correlation of r = .59897 indicates a moderate association
between the target and output optimal timings.
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